BioSpace News Archive

Increased number of research activities in all worldwide locations is projected to boost the expansion of the global polyclonal antibody market throughout the forecast period 2020–2030.

Vincerx Pharma, Inc. (Nasdaq: VINC), announced that the Company has joined the broad-market Russell 3000 and Microcap® Indexes as part of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens today, Monday, June 28, 2021.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointment of veteran biopharmaceutical leader, Scott Brun, M.D., to its Board of Directors.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC).

BioVie Inc. (NASDAQ: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today announced has been added as a member of the broad-market Russell Microcap Index

Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in collaboration with Yonsei University of Seoul, South Korea.

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the acquisition of Valley Biomedical Products & Services, Inc. located in Winchester, VA.

Felix Biotechnology today announced the initiation of a research project with Biocogent, the leading provider of high technology products and services to the personal care and cosmetic industries.

Antares Pharma, Inc. today announced that its partner Idorsia Ltd (“Idorsia”) initiated its Phase 3 registration study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y 12 receptor antagonist, in suspected acute myocardial infarction (“AMI”) utilizing Antares’ Quickshot ® auto-injector.

Shockwave Medical, Inc. (NASDAQ: SWAV), announced today that the safety, efficacy and mechanism of benefit of IVL for the treatment of coronary and peripheral artery disease has been further elucidated with the publication of three separate manuscripts in the June 28, 2021 issue of the Journal of the American College of Cardiology: Cardiovascular Interventions (JACC CI)